Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: Potential New Treatment for Anemia in Chronic Kidney Disease

Dr. Jo-Anne Wilson, BSc.Pharm, ACPR, PharmD,
Clinical Pharmacy Coordinator, NSHA Renal Program, Division of Nephrology and Associate Professor, Faculty of Health, Dalhousie University, Halifax, Nova Scotia
Outline

• Discuss the mechanism of action of hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs).

• Provide an overview of ongoing and completed trials for roxadustat, vadadustat and daprodustat.

• Review current efficacy and safety data for the HIF-PHIs.

• Summarize the pharmacokinetics and pharmacodynamics of roxadustat, vadadustat and daprodustat.

• Compare the advantages and disadvantages of HIF-PHIs over erythropoietin stimulating agents.
## HIF-PH Inhibitors (HIF-PHI)

<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Investigational Name</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Roxadustat</td>
<td>FG-4592</td>
<td>FibroGen, Astellas, &amp; AstraZeneca (Canada)</td>
</tr>
<tr>
<td>Vadadustat</td>
<td>AKB-6548</td>
<td>Akebia, Otsuka (Canada), Mitsubishi Tanahe Pharma Corporation (Japan)</td>
</tr>
<tr>
<td>Daprodustat</td>
<td>GSK-12788863</td>
<td>GlaxoSmithKline</td>
</tr>
<tr>
<td>Molidustat</td>
<td>BAY-85-3934</td>
<td>Bayer</td>
</tr>
</tbody>
</table>
## Pipeline Approval of HIF-PHIs

<table>
<thead>
<tr>
<th>HIF-PHIs</th>
<th>Pipeline</th>
</tr>
</thead>
</table>
| Roxadustat | • Approved December 2018 for DD-CKD (China)  
              • Approved August 2019 for NDD-CKD (China)  
              • Approved September 2019 for DD-CKD (Japan)  
              • FDA submission anticipated Fall 2019 and Health Canada after US filing |
| Vadadustat | • New drug application submitted July 2019 (Japan)  
              • Health Canada submission anticipated 2020/2021 |
| Daprodustat| • Health Canada submission anticipated 2020/2021                         |
Effect of Altitude on Dosing and Response to Erythropoietin in End Stage Renal Disease

Figure 1. Map of average county-level elevation of patients in study cohort.

Figure 2. (A) Average hematocrit by elevation group and time period. (B) Average EPO dose by elevation group and time period. (C) EPO resistance (EPO dose/hematocrit) by elevation group.

HIF-PHI increases Erythropoietin Production in ESRD

Figure 1. FG-2216 increases plasma-EPO levels in healthy controls and in HD patients with and without remaining renal tissue. Twenty-four-hour kinetics of plasma EPO levels after a single dose of FG-2216. (A through C) Individual values are depicted for control subjects (A), nephric HD patients (B), and anephric HD patients (C). All individuals except one received FG-2216 at a dosage of 20 mg/kg; patient 4 in the anephric group (blue line in C) was accidentally underdosed with approximately 4 mg/kg.

Mechanism of Action of HIF-PHIs
• Provide a summary of ongoing and completed Phase III trials for roxadustat, vadadustat and daprodustat
Roxadustat Phase III (Alpine) Program for Treatment of Anemia Due to CKD

**NDD-CKD Studies**
- **OLYMPUS**
  - Roxadustat vs. Placebo
- **ALPS**
  - Roxadustat vs. Placebo
- **ANDES**
  - Roxadustat vs. Placebo

**DD-CKD Studies**
- **ROCKIES**
  - Roxadustat vs. Epoetin alfa
- **SIERRAS**
  - Roxadustat vs. Epoetin alfa
- **PYRENEES**
  - Roxadustat vs. Epoetin alfa or Darbepoetin alfa
- **HIMALAYAS**
  - Roxadustat vs. Epoetin alfa

Completed – Top Line Results Available
Vadadustat Phase III Program for Treatment of Anemia Due to CKD

<table>
<thead>
<tr>
<th>Randomized, Open-Label, Active-Controlled, Non-Inferiority Phase 3 Cardiovascular Outcomes Studies</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Non-dialysis dependent (NDD)</strong>&lt;br&gt;N = up to 3700</td>
</tr>
<tr>
<td>PROTÉTECT CORRECTION&lt;br&gt;Not ESA Treated&lt;br&gt;Vadadustat vs Darbepoetin Alfa</td>
</tr>
<tr>
<td>PROTÉTECT CONVERSION&lt;br&gt;ESA Treated&lt;br&gt;Vadadustat vs Darbepoetin Alfa</td>
</tr>
<tr>
<td><strong>Dialysis dependent (DD)</strong>&lt;br&gt;N = approx. 3900</td>
</tr>
<tr>
<td>INNOVATE CORRECTION&lt;br&gt;New-Onset Dialysis*&lt;br&gt;Vadadustat vs Darbepoetin Alfa</td>
</tr>
<tr>
<td>INNOVATE CONVERSION&lt;br&gt;ESA Treated&lt;br&gt;Vadadustat vs Darbepoetin Alfa</td>
</tr>
</tbody>
</table>

Primary Efficacy Endpoint: Change in hemoglobin (Hb) from baseline
Primary Safety Endpoint: Major Adverse Cardiovascular Events (MACE)

*≤ 16 weeks of dialysis treatment, with or without prior ESA treatment
# Daprodustat Phase III Program for Treatment of Anemia Due to CKD

<table>
<thead>
<tr>
<th>Trial name</th>
<th>Comparator(s)</th>
<th>ClinicalTrials.gov identifier</th>
<th>Estimated primary completion date; estimated enrollment</th>
</tr>
</thead>
<tbody>
<tr>
<td>A Study to Evaluate Efficacy and Safety of Daprodustat Compared to Darbepoetin Alfa in Japanese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD)</td>
<td>Darbepoetin alfa</td>
<td>NCT02969655</td>
<td>July 2018; 270 patients</td>
</tr>
<tr>
<td>A Study to Evaluate the Efficacy and Safety of Daprodustat Compared to Recombinant Human Erythropoietin (rhEPO) in Subjects With Anemia Associated With Chronic Kidney Disease (CKD) Who Are Initiating Dialysis</td>
<td>Darbepoetin alfa</td>
<td>NCT03029208</td>
<td>November 2019; 300 patients</td>
</tr>
<tr>
<td><strong>Anemia Studies in Chronic Kidney Disease:</strong> Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)**</td>
<td>rhEPO</td>
<td>NCT02879305</td>
<td>April 2020; 3000 patients</td>
</tr>
<tr>
<td><strong>Anemia Studies in Chronic Kidney Disease:</strong> Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non Dialysis (ASCEND-ND)**</td>
<td>Darbepoetin alfa</td>
<td>NCT02876835</td>
<td>January 2021; 4500 patients</td>
</tr>
</tbody>
</table>
• Review current efficacy and safety data for the HIF-PHIs
Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis


Figure 1. Mean Hemoglobin Levels over Time and Hepcidin Levels and Mean Change from Baseline at Week 27 (Intention-to-Treat Population).

The intention-to-treat population (full analysis set) included all the patients who underwent randomization and had baseline and postbaseline hemoglobin values assessed during treatment. 1 bars (Panel A) and T bars (Panel B) indicate the standard error.
Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis


Figure 1. Hemoglobin and Hepcidin Levels.
Shown are the mean hemoglobin levels (Panel A) and mean hepcidin levels and the change from baseline (Panel B) during the 8-week double-blind period. The least-squares mean difference in hemoglobin values was 1.9±0.2 g per deciliter (95% confidence interval [CI], 1.4 to 2.4); the least-squares mean difference in hepcidin values was −49.77 (95% CI, −66.75 to −32.79). In Panel A, the average for weeks 7 through 9 (the measure that was used in the primary end point) is shown to the right of the graph. In Panel B, hepcidin measurements were not available for one patient in the roxadustat group. The error bars in the two panels indicate standard errors.
Roxadustat Phase III (Alpine) Program – Top line results

**NDD-CKD Studies**
- Demonstrated significantly greater efficacy vs. Placebo for change in Hb from baseline over weeks 28-52 in ALPs, ANDES, and OLYMPUS

**DD-CKD Studies**
- ROCKIES, SIERRAS, HIMALAYAS demonstrated superiority vs. epoetin alfa for mean change in Hb from baseline averaged over weeks 28-52.
FibroGen Announces Positive Topline Results from Pooled Safety Analyses of Roxadustat Global Phase 3 Program

MACE/MACE+ endpoints evaluated across CKD patients not on dialysis and on dialysis Superiority in time to first MACE+ versus epoetin alfa in incident dialysis patients

Pooled MACE/MACE+ in NDD patients

In the pooled analysis of over 4,300 patients, and based on the totality of the adjudicated evidence, the MACE/MACE+ analyses between roxadustat and placebo showed no clinically-meaningful difference.

Pooled MACE/MACE+ in ID patients

In the pool of 1,500 ID patients, a pre-specified sub-population of DD patients, MACE/MACE+ results indicate that ID patients on roxadustat do better than those who are on epoetin alfa. ID patients are a better population to compare roxadustat vs. epoetin alfa than the stable dialysis population, where patients are stable not only on dialysis but also on erythropoietin.

Pooled MACE/MACE+ in DD patients

In the pooled analysis of around 4,000 patients, and based on the totality of the adjudicated evidence, the MACE/MACE+ analyses between roxadustat and epoetin alfa showed no clinically-meaningful difference.
• Summarize the pharmacokinetics and pharmacodynamics of HIF-PHIs
  • Transiently ↑ endogenous EPO levels within or near physiologic range
  • Dose-dependently ↑ Hgb levels
  • Improves iron utilization
  • ↓ hepcidin
  • ↓ cholesterol levels

Roxadustat (FG-4592): Correction of Anemia in Incident Dialysis Patients

Anatole Besarab,† Elena Chernyavskaya,† Igor Motylev,‡ Evgeny Shutov,§ Lalathaksha M. Kumbar,⊥ Konstantin Gurevich,¶ Daniel Tak Mao Chan,**, Robert Leong,* Lona Poole,* Ming Zhong,* Khalil G. Saikali,* Marietta Franco,* Stefan Hemmerich,* Kin-Hung Peony Yu,* and Thomas B. Neff*

Figure 2. Mean hemoglobin levels over time are similar through 7 weeks for all treatment groups and thereafter lower for the no-iron vs oral or IV iron groups. Data are for the EE population using last-observation-carried-forward imputation for missing data and are expressed as the mean±SEM Hb value at each time point. Week 0 (baseline) is the mean of three predosing Hb values. *P<0.05 in comparisons between no-iron cohort to the pooled iron cohorts based on the repeated-measures analysis of covariance model with baseline Hb and iron repletion status as covariates, using all observed data collected during treatment.
Change from baseline in Iron Use Parameters

<table>
<thead>
<tr>
<th>Mean (SD) Levels</th>
<th>Baseline (n=143)</th>
<th>Change from Baseline</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>16 Weeks (n=103)</td>
<td>P-Value</td>
</tr>
<tr>
<td>Hepcidin (ng/mL)</td>
<td>119.7 (107.6)</td>
<td>-27.7 (107.2) 0.004</td>
</tr>
<tr>
<td>Serum iron (µg/dL)</td>
<td>64.0 (21.7)</td>
<td>1.1 (30.0) n. s.</td>
</tr>
<tr>
<td>TSAT (%)</td>
<td>22.0 (7.7)</td>
<td>-2.7 (8.6) 0.002</td>
</tr>
<tr>
<td>Ferritin (ng/mL)</td>
<td>278 (246)</td>
<td>-85.9 (112.6) &lt;0.001</td>
</tr>
<tr>
<td>TIBC (µg/dL)</td>
<td>261.5 (50.7)</td>
<td>40.4 (41.0) &lt;0.001</td>
</tr>
<tr>
<td>MCV (fL)</td>
<td>93.4 (61)</td>
<td>1.2 (4.5) 0.001</td>
</tr>
<tr>
<td>Clr (pg)</td>
<td>30.7 (2.4)</td>
<td>0.2 (2.0) n. s.</td>
</tr>
<tr>
<td>Platelets (x10^9/L)</td>
<td>255 (88)</td>
<td>-12.5 (61.2) 0.008</td>
</tr>
</tbody>
</table>

All cohorts were combined. Baseline is defined as the mean of the last three available values pre-1st dose. P-values are from ANOVA model comparing change from BL with zero utilizing the pooled variance from all groups. EOS (end of study) was 4 weeks post-end of treatment.

1n=137, 102, and 116, respectively.
2n=143, 103, and 123, respectively.
3TIBC: total iron binding capacity, n=145, 102, and 122 (Safety Population), respectively.
4n=143, 128, and 127, respectively.
5n=136, 96, and 117, respectively.
6n=143, 128 and 128, respectively.

<table>
<thead>
<tr>
<th>Property</th>
<th>Roxadustat</th>
<th>Vadadustat</th>
<th>Daprodustat</th>
</tr>
</thead>
<tbody>
<tr>
<td>Half-life, h</td>
<td>10-12</td>
<td>4.5</td>
<td>4</td>
</tr>
<tr>
<td><strong>Dosing Frequency</strong></td>
<td>3X/week</td>
<td>Daily</td>
<td>Daily</td>
</tr>
<tr>
<td>Dialyzable</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td><strong>Starting Dose</strong></td>
<td>100 mg po TIW (45 to &lt; 60kg)</td>
<td>300 mg po daily (150 mg tablets)</td>
<td>2-4 mg po daily (dosed in 2 mg increments)</td>
</tr>
<tr>
<td>(dosing from trials)</td>
<td>120 mg po TIW (≥ 60kg) (20 mg, 50 mg capsules)</td>
<td>With or without food</td>
<td>With or without food</td>
</tr>
<tr>
<td>Dose adjustments Q4 wks</td>
<td>With or without food</td>
<td>With or without food</td>
<td>With or without food</td>
</tr>
<tr>
<td><strong>Drug Interactions</strong></td>
<td>1 h spacing before or after phosphate binders (sevelamer carbonate, calcium acetate), oral iron, magnesium/ aluminium-containing antacids or other multivalent cation-containing drugs and supplements &lt;br&gt; Probenecid (UGT and OAT1/OAT3 inhibitor) &lt;br&gt; - Teriflunomide (OAT1/OAT3 inhibitor), Valproic acid (UGT inhibitor), Rifampin (UGT inducer) &lt;br&gt; Rosuvastatin &lt;br&gt; Gemfibrozil (CYP2C8 and OATP1B1 inhibitor) &lt;br&gt; - Cyclosporine (OATP1B1), Clopidogrel (CYP2C8), Rifampin (CYP2C8 inducer)</td>
<td>Weak CYP 2C9 inhibitor (atorvastatin, rosvastatin) &lt;br&gt; Oral Iron</td>
<td>CYP2C8 inhibitor (gemfibrozil) &lt;br&gt; CYP2C8 inducer (rifampin)</td>
</tr>
<tr>
<td><strong>Adverse Effects</strong></td>
<td>Nausea, vomiting, diarrhea, hyperkalemia, metabolic acidosis</td>
<td>Nausea, diarrhea, vomiting</td>
<td>Nausea Dyspepsia</td>
</tr>
<tr>
<td><strong>Precautions</strong></td>
<td>Moderate hepatic impairment</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
• Compare the advantages and disadvantages of HIF-PHIs over erythropoietin stimulating agents
Advantages and Disadvantages of HIF-PHIs over ESAs

**HIF-PHIs**
- Oral (NDD-CKD, PD)
- Maintain plasma EPO levels within or near normal physiologic range (negating concerns about high EPO levels with ESA agents)
- Improves FID (↓ hepcidin, ↓ ferritin and ↓ TSAT by increasing TIBC) – may require less iron therapy
- May be beneficial in inflamed patients who are hyporesponsive to ESA
- ↓ serum cholesterol (↓ LDL and ↑ HDL) (Roxa)
- Neutral effect on Bp (Roxa), ? ↑ BP (Vada)
- Long-term safety? Activation of HIF system (VEGF, tumor growth, worsening retinopathy), hepatic injury

**ESAs**
- Parenteral (NDD-CKD, PD)
- $$$
- Refrigeration (Cold Chain requirement)
- 25% of patients have ESA resistance
- Worsening blood pressure
- Cardiovascular, thromboembolic and cancer risk
Questions or Comments?